EquityZen Growth Technology Fund LLC - Series 1757
Raised
$383K
Investors
21
Min Invest
$5,006
AltStreet Analysis
·Generated from EDGAR primary sources
EquityZen Growth Technology Fund LLC - Series 1757 is a Delaware pooled investment fund vehicle filing under Rule 506(b) and Section 3(c)(1). Filed March 2024 by EquityZen Advisors and Phil Haslett, the series raised $383K from 21 investors with a $5K minimum investment. Part of EquityZen's platform of nearly 1,900 EDGAR-registered pre-IPO access vehicles.
This pre-IPO fund follows the standard 506(b)/3(c)(1) exemption pattern common to retail-accessible secondary market vehicles, with a low $5K minimum enabling broad participation. The $383K raise and 21-investor base reflect a typical single-company SPV structure within platform-managed series offerings.
Data Flags
EDGAR Filing Data
Form D — Primary Source
View on SEC.govRelated Persons (Form D)
Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.
EquityZen Advisors LLC
Executive Officer, Director · New York, NY
Phil Haslett
Executive Officer, Director · New York, NY
Is this your offering?
Claim this profile to add contact information, team members, LinkedIn profiles, fund history, and additional financial data. EDGAR-sourced data and AltStreet analysis cannot be edited, but corrections can be requested for verifiable inaccuracies.
Data Methodology
Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.
